Study of Severe COVID-19 Helps Uncover the Roots of Sepsis

Decorative image of the COVID-19 Learning Lounge

Study of Severe COVID-19 Helps Uncover the Roots of Sepsis

SUMMARY

Research at Massachusetts General Hospital and the Broad Institute of MIT and Harvard identified a higher abundance and activity of MS1 cells in severe cases of COVID-19 who had progressed to sepsis than in healthy controls. "The response to infection is complex, but work like this helps us to fill in the knowledge gaps and uncover new possibilities for treatment," said Nir Hacohen, PhD, director of the Massachusetts General Hospital Center for Cancer Immunotherapy.

FEATURED EXPERT

Nir Hacohen, PhD, director of the Massachusetts General Hospital Center for Cancer Immunotherapy and Broad

GET STARTED

Researchers find a cell type that impairs a patient's response to COVID-19 after progressing to sepsis.

Take me there now!

Read Time: 3 minutes

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

US Solutions

VIDAS^® B•R•A•H•M•S PCT™

Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

Learn More

PUBLISHED BY

Medical Xpress
June 9, 2021